|
Product Detail :
|
Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8 Sgb V On The Active Ingredient Adefovir Dipivoxil
|
| Tender Detail : |
Contract notice: Conclusion of non-exclusive discount agreements in accordance with Section 130a paragraph. 8 sgb v on the active ingredient adefovir dipivoxil
ยง130a para. 8 sgb v enables health insurance companies (kk) and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory kk. The gwq is a company for efficiency and quality at kk in accordance with Section 130a paragraph. 8 s. 5 sgb v for their shareholders and customers funds. With regard to the relevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal procurement procedures takes place in accordance with the regulations of Part 4 of the GWB by GWQ Serviceplus AG. Until new drug discount agreements come into force, gwq would like to conclude drug discount agreements with all interested pharmaceutical companies as part of the open-house procedure for preparations with the above-mentioned active ingredient. The earliest contract start date is November 1st, 2023.gwq serviceplus ag intends to enter into non-exclusive discount agreements in accordance with Section 130a paragraph. 8 sgb v also oa active substance with contract start on November 1st, 2023. All interested companies can join this contract at any time during the contract term under the same conditions (approval model). The gwq assumes that this procedure does not fall within the scope of antitrust procurement law due to the lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance companies and their sales as well as the dates for reporting the contract can be viewed and downloaded on the gwq serviceplus ag procurement portal at http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants to join. If the signed contracts/declaration and evidence are received by October 10th, 2023, an initial notification can be made on November 1st, 2023. The following documents must be submitted: - signed contract in duplicate, - proof of the drug approval via an extract from the public part of the amice database, โ signed self-declaration (annex 3), โ list of PZN covered by the contract (annex 2), โ declaration on council regulation (eu) 2022/576 of April 8, 2022 amending regulation (eu) no. 833/2014 on restrictive measures in view of Russia&39;s actions destabilizing the situation in Ukraine (Appendix 5)
|